

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |   |
|---|---|----|---|--------------------------|---|
| <b>Substitute for form 1449/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |   |
|   |   |    |   | Application Number       | 10/591,962 (Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                 |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                          |
|   |   |    |   | Art Unit                 | To Be Assigned                                |
|   |   |    |   | Examiner Name            | To Be Assigned                                |
| Sheet   | 1 | of | 3 | Attorney Docket Number   | 2451.0130000/BJD/GER                          |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |   |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (if Known) |                                |  |   |
|                       | US1                   | 2,934,556                                | 04/26/1960                     | Hoffmann <i>et al.</i>                             |   |
|                       | US2                   | 4,499,082                                | 02/12/1985                     | Shenvi <i>et al.</i>                               |   |
|                       | US3                   | 4,701,545                                | 10/20/1987                     | Matteson <i>et al.</i>                             |   |
|                       | US4                   | 4,927,809                                | 05/22/1990                     | Stüber   |   |
|                       | US5                   | 4,935,493                                | 06/19/1990                     | Bachovchin <i>et al.</i>                           |   |
|                       | US6                   | 4,963,655                                | 10/16/1990                     | Kinder <i>et al.</i>                               |   |
|                       | US7                   | 5,169,841                                | 12/08/1992                     | Kleeman <i>et al.</i>                              |   |
|                       | US8                   | 5,187,157                                | 02/16/1993                     | Kettner <i>et al.</i>                              |   |
|                       | US9                   | 5,444,049                                | 08/22/1995                     | de Nanteuil <i>et al.</i>                          |   |
|                       | US10                  | 5,462,964                                | 10/31/1995                     | Fevig <i>et al.</i>                                |   |
|                       | US11                  | 5,563,127                                | 10/08/1996                     | Amparo <i>et al.</i>                               |   |
|                       | US12                  | 5,574,014                                | 11/12/1996                     | Claeson <i>et al.</i>                              |   |
|                       | US13                  | 5,585,360                                | 12/17/1996                     | de Nanteuil <i>et al.</i>                          |   |
|                       | US14                  | 5,596,123                                | 01/21/1997                     | Elgendy <i>et al.</i>                              |   |
|                       | US15                  | 5,639,739                                | 06/17/1997                     | Dominguez <i>et al.</i>                            |   |
|                       | US16                  | 5,658,885                                | 08/19/1997                     | Lee <i>et al.</i>                                  |   |
|                       | US17                  | 5,681,978                                | 10/28/1997                     | Matteson <i>et al.</i>                             |   |
|                       | US18                  | 5,731,439                                | 03/24/1998                     | Carini <i>et al.</i>                               |   |
|                       | US19                  | 5,780,454                                | 06/14/1998                     | Adams <i>et al.</i>                                |   |
|                       | US20                  | 5,814,622                                | 09/29/1998                     | de Nanteuil <i>et al.</i>                          |   |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |  |                |
|--------------------------|-----------------------|---|--------------------------------|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document                                 | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                |  |                |
|                          | FP1                   | WO 89/09612 A1  | 10/19/1989                     | Corvas, Inc.   |                |
|                          | FP2                   | EP 0 471 651 A2   | 02/19/1992                     | Sandoz Ltd.; Sandoz-Patent-GmbH; Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H. |                |
|                          | FP3                   | WO 92/07869 A1  | 05/14/1992                     | Thrombosis Res. Institute; Kakkar <i>et al.</i>                                    |                |
|                          | FP4                   | EP 0 599 633 A1   | 06/01/1994                     | Thrombosis Research Institute  |                |
|                          | FP5                   | WO 94/21668 A1  | 09/29/1994                     | The Du Point Merck Pharmaceutical Co.  |                |
|                          | FP6                   | WO 94/21650 A1  | 09/29/1994                     | The Du Point Merck Pharmaceutical Co.  |                |
|                          | FP7                   | WO 94/25049 A1  | 11/10/1994                     | The Du Point Merck Pharmaceutical Co.  |                |
|                          | FP8                   | WO 95/09858 A1  | 04/13/1995                     | The Du Point Merck Pharmaceutical Co.  |                |
|                          | FP9                   | WO 95/09859 A1  | 04/13/1995                     | The Du Point Merck Pharmaceutical Co.  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |   |
|---|---|----|---|--------------------------|---|
| <b>Substitute for form 1449/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |   |
|   |   |    |   | Application Number       | 10/591,962 (Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                 |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                          |
|   |   |    |   | Art Unit                 | To Be Assigned                                |
|   |   |    |   | Examiner Name            | To Be Assigned                                |
| Sheet   | 2 | of | 3 | Attorney Docket Number   | 2451.0130000/BJD/GER                          |

| U.S. PATENT DOCUMENTS    |                       |  |                                |  |   |
|--------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*       | Cite No. <sup>1</sup> | Document Number  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document                                 | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                          |                       | Number-Kind Code <sup>2</sup> (If Known)   |                                |  |   |
|                          | US20                  | 6,066,730  | 05/23/2000                     | Adams <i>et al.</i>  |   |
|                          | US21                  | 6,083,903  | 07/04/2000                     | Adams <i>et al.</i>  |   |
|                          | US22                  | 6,114,308  | 09/05/2000                     | Claeson <i>et al.</i>  |   |
|                          | US24                  | 6,297,217 B1   | 10/02/2001                     | Adams <i>et al.</i>  |   |
|                          | US25                  | 6,313,096 B1   | 11/06/2001                     | Claeson <i>et al.</i>  |   |
|                          | US26                  | 6,417,174 B1   | 07/09/2002                     | Shoichet <i>et al.</i>   |   |
|                          | US27                  | 6,465,433 B1   | 10/15/2002                     | Adams <i>et al.</i>  |   |
|                          | US28                  | 6,617,317 B1   | 09/09/2003                     | Adams <i>et al.</i>  |   |
|                          | US29                  | 6,699,835 B2   | 03/02/2004                     | Plamondon <i>et al.</i>  |   |
|                          | US30                  | 6,713,446 B2   | 03/30/2004                     | Gupta  |   |
|                          | US31                  | 6,747,150 B2   | 06/08/2004                     | Adams <i>et al.</i>  |   |
|                          | US32                  | 7,112,572 B2   | 09/26/2006                     | Deadman <i>et al.</i>  |   |
|                          | US33                  | 7,112,590 B2   | 09/26/2006                     | Kikelj <i>et al.</i>   |   |
|                          | US34                  | 2004/0138175 A1  | 07/15/2004                     | Madge <i>et al.</i>  |   |
|                          | US35                  | 2005/0119226 A1  | 06/02/2005                     | Walter <i>et al.</i>   |   |
|                          | US36                  | 2005/0176651 A1  | 08/11/2005                     | Madge <i>et al.</i>  |   |
|                          | US37                  | 2005/0282757 A1  | 12/22/2005                     | Combe-Marzelle <i>et al.</i>   |   |
|                          | US38                  | 2005/0288253 A1  | 12/29/2005                     | Madge <i>et al.</i>  |   |
|                          | US39                  | 2006/0084592 A1  | 04/20/2006                     | Boucher  |   |
|                          | US40                  | 2006/0172978 A1  | 08/03/2006                     | Russell <i>et al.</i>  |   |
|                          | US41                  | 2006/0172920 A1  | 08/03/2006                     | Scully <i>et al.</i>   |   |
| FOREIGN PATENT DOCUMENTS |                       |  |                                |  |   |
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document                                 | T <sup>6</sup>  |
|                          |                       | Country Code <sup>3</sup> Number <sup>4</sup><br>Kind Code <sup>5</sup> (if known) |                                |  |   |
|                          | FP10                  | WO 95/09634 A1   | 04/13/1995                     | The Du Point Merck Pharmaceutical Co.  |   |
|                          | FP11                  | WO 96/12499 A1   | 02/05/1996                     | The Du Point Merck Pharmaceutical Co.  |   |
|                          | FP12                  | WO 96/13266 A1   | 05/09/1996                     | Proscript, Inc.  |   |
|                          | FP13                  | WO 96/20689 A2   | 07/11/1996                     | The Du Point Merck Pharmaceutical Co.  |   |
|                          | FP14                  | WO 97/05161 A1   | 02/13/1997                     | Sandoz-Patent-GmbH; Sandoz-Erfindungen<br>Verwaltungsgesellschaft MbH; Wienand, A. |   |
|                          | FP15                  | WO 98/00443 A1   | 01/08/1998                     | Thrombosis Research Institute; Deadman <i>et al.</i>                               |   |
|                          | FP16                  | WO 98/31688 A1   | 07/23/1998                     | Adir et Compagnie; Cordi <i>et al.</i>   | Abs   |
|                          | FP17                  | WO 99/26652 A1   | 06/03/1999                     | Danbiosyst UK Ltd.; Watts <i>et al.</i>  |   |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                    |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |   |    |   | Art Unit                 | To Be Assigned                                   |
|   |   |    |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 1 | of | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |

| NON PATENT LITERATURE DOCUMENTS |                       |   |  |  |
|---------------------------------|-----------------------|---|--|--|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  |  |  |
|                                 | NPL1                  | Bastin, R.J., <i>et al.</i> , "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," <i>Org. Proc. Res. Devel.</i> 4:427-435, American Chemical Society and The Royal Society of Chemistry (2000)                               |  |  |
|                                 | NPL2                  | Berge, S.M., <i>et al.</i> , "Pharmaceutical Salts," <i>J. Pharm. Sci.</i> 66:1-19, Wiley (1977)  |  |  |
|                                 | NPL3                  | Brikh, A., and Morin, C., "Boronated thiophenols: a preparation of 4-mercaptophenylboronic acid and derivatives," <i>J. Organometallic Chem.</i> 581:82-86 (1999)   |  |  |
|                                 | NPL4                  | Carr, J.A., and Silverman, N., "The heparin-protamine interaction," <i>J. Cardiovasc. Surg.</i> 40:659-666, Minerva Medica (1999)   |  |  |
|                                 | NPL5                  | Chahwala, S.B., <i>et al.</i> , "TRI 50, a Potent and Selective Orally Active Direct Thrombin Inhibitor," <i>Blood</i> 102:814a, American Society of Hematology (2003)  |  |  |
|                                 | NPL6                  | Claeson, G., "Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system," <i>Blood Coagul. Fibrinolysis</i> 5:411-436, Rapid Communications of Oxford Ltd. (1994)                     |  |  |
|                                 | NPL7                  | Claeson, G., <i>et al.</i> , "Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position," <i>Biochem J.</i> 290:309-312, Portland Press (1993)               |  |  |
|                                 | NPL8                  | Claeson, G., <i>et al.</i> , "Design of Novel Types of Thrombin Inhibitors Based on Modified D-PHE-PRO-ARG Sequences," in <i>The Design of Synthetic Inhibitors of Thrombin</i> , Claeson G., <i>et al.</i> , eds., Plenum Press, New York, NY pp. 83-89 (1993) |  |  |
|                                 | NPL9                  | Claeson, G., <i>et al.</i> , "Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences," in <i>Peptide, Chemistry and Biology</i> , Smith, J.A., and River, J.E., eds., Escom: Linden, pp. 824-825 (1992)    |  |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                    |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |   |    |   | Art Unit                 | To Be Assigned                                   |
|   |   |    |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 2 | of | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T <sup>2</sup> |
|                                 | NPL10                 | Claeson, G., <i>et al.</i> , "New Peptide Boronic Acid Inhibitor of Thrombin," <i>Thromb. Haemost.</i> 65:1289, Schattauer (1991)   |                |
|                                 | NPL11                 | Coburn, C.A., "Small-molecule direct thrombin inhibitors: 1997-2000," <i>Exp. Opin. Ther. Patents</i> 11:721-738, Ashley Publications Ltd. (2001)   |                |
|                                 | NPL12                 | Contreras, R., <i>et al.</i> , "The N-B Coordination in Hindered Cyclic-Thexylboronic Esters Derived from Diethanolamines," <i>J. Organometallic Chem.</i> 246:213-217, Elsevier Sequoia S.A. (1983)  |                |
|                                 | NPL13                 | Davies, A.G., <i>et al.</i> , "Peroxides of Elements other than Carbon. Part XII. The Autoxidation of Optically Active 1-Phenylethylboronic Acid," <i>J. Chem. Soc. B:</i> 17-22, Chemical Society (1967)   |                |
|                                 | NPL14                 | Davies, G., "Changing the Salt, Changing the Drug," <i>Pharmaceut. J.</i> 266:322-323, Wiley (2001)   |                |
|                                 | NPL15                 | Deadman, J., <i>et al.</i> , "Structure/Function Aspects of Neutral P1 Residue Peptide Inhibitors of Thrombin," <i>J. Enzym. Inhib.</i> 9:29-41, Harwood Academic Publishers GmbH (1995)  |                |
|                                 | NPL16                 | Deadman, J.J., <i>et al.</i> , "Characterization of a Class of Peptide Boronates with Neutral P1 Side Chains as Highly Selective Inhibitors of Thrombin," <i>J. Med. Chem.</i> 38:1511-1522, American Chemical Society (1995)                         |                |
|                                 | NPL17                 | Elgendy, S., <i>et al.</i> , "Facile Routes to 1-Halo-1-Alkyl Boronic Esters as Precursors for Novel Thrombin Inhibitors," <i>Tetrahedron</i> 50:3803-3812, Elsevier Science Ltd. (1994)  |                |
|                                 | NPL18                 | Elgendy, S., <i>et al.</i> , "New Peptide Boronic Acid Inhibitors of Thrombin," <i>Tetrahedron Lett.</i> 33:4209-4212, Pergamon Press Ltd. (1992)   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |                          |   |   |                          |  |
|---|--------------------------|---|---|--------------------------|--|
| Substitute for form 1449/PTO  |                          |   |   | <b>Complete if Known</b> |  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |                          |   |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |                          |   |   | Intl. Filing Date        | March 9, 2005                                    |
|   |                          |   |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |                          |   |   | Art Unit                 | To Be Assigned                                   |
|   |                          |   |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 3                        | of  | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |
| <b>NON PATENT LITERATURE DOCUMENTS</b>  |                          |   |   |                          |  |
| Examiner<br>Initials*   | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published                           |   |                          | T <sup>2</sup>                                   |
|   | NPL19                    | Elgendy, S., <i>et al.</i> , "New Peptide Boronic Acid Inhibitors of Thrombin," in <i>The Design of Synthetic Inhibitors of Thrombin</i> , G. Claeson, <i>et al.</i> , eds., Plenum Press, New York, NY pp. 173-178 (1993)  |   |                          |  |
|   | NPL20                    | Elgendy, S., <i>et al.</i> , "Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates in solid phase chemistry," <i>Tetrahedron Lett.</i> 38:3305-3308, Elsevier Science Ltd. (1997)                             |   |                          |  |
|   | NPL21                    | Elgendy, S., <i>et al.</i> , "Peptide Amino Boronic Acids as Thrombin Inhibitors. Effects on Ki and Hypotensive Side-Effects of the Modifications of the Boronic Acid Side Chain," <i>Thromb. Haemost.</i> 65:775, Schattauer (1991)  |   |                          |  |
|   | NPL22                    | Esmail, A.F., <i>et al.</i> , "Antithrombotic and Anticoagulant Properties of Novel Peptide Boronic and Thrombin Inhibitors: Comparison with Heparin and Hirudin," <i>Thromb. Haemost.</i> 73: 1318, Schattauer (1995)  |   |                          |  |
|   | NPL23                    | Esmail, A.F., <i>et al.</i> , "Effect of Triban a novel thrombin inhibitor on platelet procoagulant activity in vitro and SK induced thrombolysis In vivo," <i>Thromb. Haemost.</i> 5:498-499, Schattauer (1997)  |   |                          |  |
|   | NPL24                    | Esmail, A.F., <i>et al.</i> , "Comparison of antithrombotic properties of Triban, hirudin, heparin and aspirin in a new dynamic model of venous thrombosis," <i>Thromb. Haemost.</i> 5:91-92, Schattauer (1997)   |   |                          |  |
|   | NPL25                    | Gerrard, D., <i>et al.</i> , "Prevention of Thrombosis in a Pig Coronary Model, Comparison of the Efficacy of a Specific Thrombin Inhibitors TRI50b with Aspirin," <i>Thromb. Haemost.</i> 6:1307, Schattauer (1995)  |   |                          |  |
|   | NPL26                    | Gustafsson, D., <i>et al.</i> , "The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects," <i>Thromb. Res.</i> 101:171-181, Elsevier Science Ltd. (2001)                              |   |                          |  |
|   | NPL27                    | Hsiao, G.K., and Hangauer, D.G., "A Facile Synthesis of <i>tert</i> -Butyl 2-[(Benzyloxycarbonyl)amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid," <i>Synthesis</i> 7:1043-1046, Thieme (1997) |   |                          |  |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                    |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |   |    |   | Art Unit                 | To Be Assigned                                   |
|   |   |    |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 4 | of | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published   | T <sup>2</sup> |
|-----------------------|--------------------------|---|----------------|
|                       | NPL28                    | Katz, B.A., <i>et al.</i> , "Episelection: Novel K <sub>i</sub> ~ Nanomolar Inhibitors of Serine Proteases Selected by Binding or Chemistry on an Enzyme Surface," <i>Biochemistry</i> 34:8264-8280, American Chemical Society (1995)   |                |
|                       | NPL29                    | Kettner, C.A., and Shenvi, A.B., "Inhibition of the Serine Proteases Leukocyte Elastase, Pancreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids," <i>J. Biol. Chem.</i> 259:15106-15114, The American Society of Biological Chemists, Inc. (1984)  |                |
|                       | NPL30                    | Kettner, C., <i>et al.</i> , "The Selective Inhibition of Thrombin by Peptides of Boroarginine," <i>J. Biol. Chem.</i> 265:18289-18297, The American Society for Biochemistry and Molecular Biology, Inc. (1990)  |                |
|                       | NPL31                    | Kimmel, S.E., <i>et al.</i> , "Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary Bypass," <i>Anesth. Analg.</i> 94:1402-1408, The International Anesthesia Research Society (2002)   |                |
|                       | NPL32                    | Kimmel, S.E., <i>et al.</i> , "Adverse Events after Protamine Administration in Patients Undergoing Cardiopulmonary Bypass: Risks and Predictors of Under-Reporting," <i>J. Clin. Epidemiol.</i> 51:1-10, Elsevier Science Inc. (1998)  |                |
|                       | NPL33                    | M.F. Lappert, "Organic Compounds of Boron," <i>Chem. Rev.</i> 56:959-1064, American Chemical Society (1956)   |                |
|                       | NPL34                    | Martinchonok, V., and Jones, B.J., "Probing the Specificity of the Serine Proteases Subtilisin Carlsberg and $\alpha$ -Chymotrypsin with Enantiomeric 1-Acetamido Boronic Acids. An Unexpected Reversal of the Normal "L"-Stereoselectivity Preference," <i>J. Am. Chem. Soc.</i> 118:950-958, American Chemical Society (1996) |                |
|                       | NPL35                    | Martichonok, V., and Jones, J.B., "Cysteine Proteases such as Papain are not Inhibited by Substrate Analogue Peptidyl Boronic Acids," <i>Bioorg. Med. Chem.</i> 5:679-684, Elsevier Science Ltd. (1997)   |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |                          |   |   |                          |  |
|---|--------------------------|---|---|--------------------------|--|
| Substitute for form 1449/PTO  |                          |   |   | <b>Complete if Known</b> |  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |                          |   |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |                          |   |   | Intl. Filing Date        | March 9, 2005                                    |
|   |                          |   |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |                          |   |   | Art Unit                 | To Be Assigned                                   |
|   |                          |   |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 5                        | of  | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |
| <b>NON PATENT LITERATURE DOCUMENTS</b>  |                          |   |   |                          |  |
| Examiner<br>Initials*   | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published               |   |                          | T <sup>2</sup>                                   |
|   | NPL36                    | Matteson, D.S., "α-Halo Boronic Esters: Intermediates for Stereodirected Synthesis," <i>Chem. Rev.</i> 89:1535-1551, American Chemical Society (1989)   |   |                          |  |
|   | NPL37                    | Matteson, D.S., and Man, H.-W., "Hydrolysis of Substituted 1,3,2-Dioxaborolanes and an Asymmetric Synthesis of a Differentially Protected syn,syn-3-Methyl-2,4-hexanediol," <i>J. Org. Chem.</i> 61:6047-6051, American Chemical Society (1996)                     |   |                          |  |
|   | NPL38                    | Mauney, M.C., <i>et al.</i> , "Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine," <i>J. Vasc. Surg.</i> 22:264-270, Mosby-Year Book, Inc. (1995)  |   |                          |  |
|   | NPL39                    | McGregor, J.L., "Current Perspective on Antithrombin Drugs," <i>Pathophysiol. Haemost. Thromb.</i> 32(Suppl. 3):29-35, S. Karger AG, Basel (2002)   |   |                          |  |
|   | NPL40                    | Metternich, R., <i>et al.</i> , "In Vitro and In Vivo Evaluation of Neutral Boron Containing Thrombin Inhibitors," <i>Naunyn Schmiedebergs Arch. Pharmacol.</i> 97:387, Springer Verlag (1992)  |   |                          |  |
|   | NPL41                    | Philipp, M., <i>et al.</i> , "ph-Dependent Binding Constants for the Inhibition of Thrombin by Transition State Analogs," in <i>The Design of Synthetic Inhibitors of Thrombin</i> , Claeson, G., <i>et al.</i> , eds., Plenum Press, New York, NY pp. 67-77 (1993) |   |                          |  |
|   | NPL42                    | Rewinkel, J.B.M., and Adang, A.E.P., "Strategies and Progress Towards the Ideal Orally Active Thrombin Inhibitor," <i>Curr. Pharma. Design</i> 5:1043-1075, Bentham Science Publishers B.V. (1999)  |   |                          |  |
|   | NPL43                    | Russell, V.P., <i>et al.</i> , "A Specific Neutralizing Agent for the Direct Thrombin Inhibitor TRI 50," <i>Blood</i> 102:814a, American Society of Hematology (2003)   |   |                          |  |
|   | NPL44                    | Sanderson, P.E.J., and Naylor-Olsen, A.M., "Thrombin Inhibitor Design," <i>Curr. Med. Chem.</i> 5:299-304, Bentham Science Publishers B.V. (1998)   |   |                          |  |
|   | NPL45                    | Satoh, H., and Aungst, B.J., "Improvement of the Intestinal Absorption of a Peptidomimetic, Boronic Acid Thrombin Inhibitor Possibly Utilizing the Oligopeptide Transporter," <i>Pharma. Res.</i> 16:1786-1789, Plenum Publishing Corporation (1999)                |   |                          |  |
| Examiner<br>Signature   |                          |   |   | Date<br>Considered       |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                    |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |   |    |   | Art Unit                 | To Be Assigned                                   |
|   |   |    |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 6 | of | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |

| NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---------------------------------|--------------------------|---|----------------|
| Examiner<br>Initials*           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published                   | T <sup>2</sup> |
|                                 | NPL46                    | Skordalakes, E., <i>et al.</i> , "Bifunctional Peptide Boronate Inhibitors of Thrombin: Crystallographic Analysis of Inhibition Enhanced by Linkage to an Exosite 1 Binding Peptide," <i>Biochem.</i> 37:14420-14427, American Chemical Society (1998)                  |                |
|                                 | NPL47                    | Skordalakes, E., <i>et al.</i> , "Crystallographic Structures of Human $\alpha$ -Thrombin Complexed to Peptide Boronic Acids Lacking a Positive Charge at P1. Evidence of Novel Interactions," <i>J. Am. Chem. Soc.</i> 119:9935-9936, American Chemical Society (1997) |                |
|                                 | NPL48                    | Snyder, H.R., <i>et al.</i> , "Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids," <i>J. Am. Chem. Soc.</i> 60:105-111, American Chemical Society (1933)   |                |
|                                 | NPL49                    | Snyder, H.R., <i>et al.</i> , "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," <i>J. Am. Chem. Soc.</i> 80:3611-3615, American Chemical Society (1958)  |                |
|                                 | NPL50                    | Spencer, J., <i>et al.</i> , "Synthesis of <i>ortho</i> -modified mercapto- and piperazino-methyl-phenylboronic acid derivatives," <i>Tetrahedron</i> 58:1551-1556, Elsevier Science Ltd. (2002)  |                |
|                                 | NPL51                    | Steinmetzer, R., <i>et al.</i> , "Advances in the development of thrombin inhibitors," <i>Expert Opin. Investig. Drugs</i> 10:845-864, Ashley Publications Ltd. (2001)  |                |
|                                 | NPL52                    | Tapparelli, C., <i>et al.</i> , "In Vitro and In Vivo Characterization of a Neutral Boron-containing Thrombin Inhibitor," <i>J. Biol. Chem.</i> 258:4734-4741, The American Society for Biochemistry and Molecular Biology, Inc. (1993)                                 |                |
|                                 | NPL53                    | Tapparelli, C., <i>et al.</i> , "Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile," <i>Trends Pharmacol. Sci.</i> 14:366-375, Elsevier Science Publishers Ltd. (1993)   |                |
|                                 | NPL54                    | Trigen Limited, "Looking for a career in Biotechnology," poster exhibited at the <i>XVIITH International Symposium on Medicinal Chemistry</i> , Barcelona, Spain, September 5, 2002   |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                    |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |   |    |   | Art Unit                 | To Be Assigned                                   |
|   |   |    |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 7 | of | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |  |
|---------------------------------|-----------------------|---|----------------|--|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T <sup>2</sup> |  |
|                                 | NPL55                 | Trigen Limited, "TRI 50b Non Confidential Information", pp. 1-12, July 2002   |                |  |
|                                 | NPL56                 | Tripathy, P.B., and Matteson, D.S., "Asymmetric Synthesis of the Four Stereoisomers of 4-Methyl-3-heptanol via Boronic Esters: Sequential Double Stereodifferentiation Leads to Very High Purity," <i>Synthesis</i> 1990:200-206, Thieme (1990)       |                |  |
|                                 | NPL57                 | von Matt, A., <i>et al.</i> , "Selective Boron-Containing Thrombin Inhibitors X-ray Analysis Reveals Surprising Binding Mode," <i>Bioorg. Med. Chem.</i> 8:2291-2303, Elsevier Science Ltd. (2000)  |                |  |
|                                 | NPL58                 | Wityak, J., <i>et al.</i> , "Synthesis of Thrombin Inhibitor DuP 714," <i>J. Org. Chem.</i> 60:3717-3722, American Chemical Society (1995)  |                |  |
|                                 | NPL59                 | Wu, S., <i>et al.</i> , "Degradation Pathways of a Peptide Boronic Acid Derivative, 2-Pyz-(CO)-Phe-Leu-B(OH) <sub>2</sub> ," <i>J. Pharmaceut. Sci.</i> 89:758-765, Wiley-Liss, Inc. and the American Pharmaceutical Association (2000)               |                |  |
|                                 | NPL60                 | Yang, C.Y., <i>et al.</i> , "Intestinal Peptide Transport Systems and Oral Drug Availability," <i>Pharamaceut. Res.</i> 16:1331-1343, Plenum Publishing Corp. (1999)  |                |  |
|                                 | NPL61                 | Yang, W., <i>et al.</i> , "Boronic Acid Compounds as Potential Pharmaceutical Agents," <i>Med. Res. Rev.</i> 23:346-368, Wiley Periodicals, Inc. (2003)   |                |  |
|                                 | NPL62                 | Zavoico, G.B., "Emerging Cardiovascular Therapeutics," <i>Cardiovas. Drug Rev.</i> 21:246-253, Neva Press (2003)  |                |  |
|                                 | NPL63                 | Office Action mailed August 9, 2007 in United States Patent Application No. 10/937,181, Walter, A., <i>et al.</i> , filed September 9, 2004   |                |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| <b>Substitute for form 1449/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|   |   |    |   | Application Number       | 10/591,962<br>(Natl. Phase of PCT/GB2005/000907) |
|   |   |    |   | Intl. Filing Date        | March 9, 2005                                    |
|   |   |    |   | First Named Inventor     | PATRICK, Guy Michael                             |
|   |   |    |   | Art Unit                 | To Be Assigned                                   |
|   |   |    |   | Examiner Name            | To Be Assigned                                   |
| Sheet   | 8 | of | 8 | Attorney Docket Number   | 2451.0130000/BJD/GER                             |

| NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---------------------------------|--------------------------|---|----------------|
| Examiner<br>Initials*           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T <sup>2</sup> |
|                                 | NPL64                    | Office Action mailed February 5, 2007 in United States Patent Application No. 10/659,178, Madge, D.J., <i>et al.</i> , filed September 9, 2003  |                |
|                                 | NPL65                    | Office Action mailed May 23, 2007 in United States Patent Application No. 10/659,178, Madge, D.J., <i>et al.</i> , filed September 9, 2003  |                |
|                                 | NPL66                    | Office Action mailed July 25, 2006 in United States Patent Application No. 10/658,971, Madge, D.J., <i>et al.</i> , filed September 9, 2003   |                |
|                                 | NPL67                    | Office Action mailed January 25, 2007 in United States Patent Application No. 10/658,971, Madge, D.J., <i>et al.</i> , filed September 9, 2003  |                |
|                                 | NPL68                    | Advisory Action mailed May 10, 2007 in United States Patent Application No. 10/658,971, Madge, D.J., <i>et al.</i> , filed September 9, 2003  |                |
|                                 | NPL69                    | Office Action mailed November 29, 2007 in United States Patent Application No. 11/077,620, Boucher, O.V.A. <i>et al.</i> , filed March 9, 2005  |                |
|                                 | NPL70                    | Office Action mailed November 9, 2007 in United States Patent Application No. 11/077,620, Boucher, O.V.A. <i>et al.</i> , filed March 9, 2005   |                |
|                                 | NPL71                    | Office Action mailed November 9, 2007 in United States Patent Application No. 11/078,097, Combe-Marzelle, S.M. <i>et al.</i> , filed March 9, 2005  |                |
|                                 | NPL72                    | Office Action mailed September 19, 2007 in United States Patent Application No. 10/937,854, Madge, D.J. <i>et al.</i> , filed September 8, 2004   |                |

728880v1

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.